{"nctId":"NCT00432237","briefTitle":"Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)","startDateStruct":{"date":"2007-03"},"conditions":["Migraine"],"count":1703,"armGroups":[{"label":"MK0974 50 mg","type":"EXPERIMENTAL","interventionNames":["Drug: MK0974 50 mg"]},{"label":"MK0974 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: MK0974 150 mg"]},{"label":"MK0974 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: MK0974 300 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"MK0974 50 mg","otherNames":["MK0974"]},{"name":"MK0974 150 mg","otherNames":["MK0974"]},{"name":"MK0974 300 mg","otherNames":["MK0974"]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has at least 1 year history of migraine (with or without aura)\n* Females of childbearing years must use acceptable contraception throughout trial\n\nExclusion Criteria:\n\n* Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)\n* Patient has history or evidence of uncontrolled diabetes, or Human Immunodeficiency Virus (HIV) disease. Patient has uncontrolled cardiovascular disease\n* Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)\n* Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption\n* Patient has a history of cancer within the last 5 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Reporting Pain Freedom at 2 Hours Postdose","description":"Pain Freedom was defined as a reduction of a Grade 2 or 3 severity migraine at baseline to a no pain (Grade 0) at 2 hours post dose.\n\nHeadache severity was recorded by the patient in a diary. 0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Have Sustained Pain-Freedom From 2 to 24 Hours Postdose","description":"Pain Freedom at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache during the 24 hours after dosing with study medication.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"63","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients Reporting Pain Relief at 2 Hours Post Dose","description":"Reduction of a Grade 2 or 3 severity migraine at baseline to mild or no pain (Grade 1 or 0) at 2 hours post dose.\n\nHeadache severity was recorded by the patient in a diary. 0=no pain; 1=mild pain; 2=moderate pain; 3=severe pain.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"205","spread":null},{"groupId":"OG002","value":"205","spread":null},{"groupId":"OG003","value":"120","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients Reporting Absence of Photophobia at 2 Hours Post Dose","description":"Respective experience (yes/no) of migraine-associated symptoms (including photophobia) was recorded by the patient in a diary.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"176","spread":null},{"groupId":"OG002","value":"179","spread":null},{"groupId":"OG003","value":"119","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients Reporting Absence of Phonophobia at 2 Hours Post Dose","description":"Respective experience (yes/no) of migraine-associated symptoms (including phonophobia) was recorded by the patient in a diary.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"192","spread":null},{"groupId":"OG002","value":"206","spread":null},{"groupId":"OG003","value":"152","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients Reporting Absence of Nausea at 2 Hours Post Dose","description":"Respective experience (yes/no) of migraine-associated symptoms (including nausea) was recorded by the patient in a diary.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"260","spread":null},{"groupId":"OG002","value":"258","spread":null},{"groupId":"OG003","value":"196","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Have Total Migraine Freedom 2 to 24 Hours Postdose","description":"Pain Freedom and no migraine-associated symptoms at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache or migraine-associated symptom during the 24 hours after dosing with study medication.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"54","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Have Total Migraine Freedom 2 Hours Postdose","description":"Pain Freedom and no migraine-associated symptoms at 2 hours postdose.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"78","spread":null},{"groupId":"OG003","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":177},"commonTop":["Nausea","Dry Mouth","Fatigue","Dizziness","Somnolence"]}}}